Showing 41,061 - 41,080 results of 44,189 for search '"In Treatment"', query time: 0.19s Refine Results
  1. 41061

    First-in-human phase I trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, SL-172154 in patients with platinum-resistant ovarian cancer by Lini Pandite, Simon Metenou, Debra L Richardson, Erika Hamilton, Linda Van Le, Bo Ma, Fatima Rangwala, Nehal J Lakhani, Justin Call, Daphne Stewart, Lauren E Dockery, Guanfang Wang, Jade Huguet, Elliot Offman

    Published 2025-01-01
    “…Objectives included evaluation of safety, dose-limiting toxicity, recommended phase II dose, pharmacokinetic (PK) and pharmacodynamic (PD) parameters, and antitumor activity.Results 27 patients (median age 66 years (range, 33–85); median of 4 prior systemic therapies (range, 2–9)) with ovarian (70%), fallopian tube (15%), or primary peritoneal (15%) cancer received SL-172154. Treatment-emergent adverse events (TEAEs) were reported for 27 patients (100%), with 24 (88.9%) having a drug-related TEAE and infusion-related reactions being the most common. 12 patients (44.4%) had grade 3/4 TEAEs, and half of these patients (22.2%) had a drug-related grade 3/4 TEAE. …”
    Get full text
    Article
  2. 41062
  3. 41063
  4. 41064

    Effect of Yanshiqiangxin Decoction on Cardiomyocyte Apoptosis in Heart Failure Rats Based on PI3K/Akt/Caspase-9 Signaling Pathway by ZHU Sixing, YAN Shiyun, XU Yan, QIN Yan, CHEN Liyun, JIA Meijun

    Published 2022-04-01
    “…ObjectiveTo detect the effect of Yanshiqiangxin decoction on apoptosis of cardiomyocytes in rats with heart failure based on PI3K/Akt/Caspase-9 signalling pathway and to explore the possible mechanism of Yanshiqiangxin decoction in the treatment of heart failure.MethodsA total of 60 Wistar male rats were randomly divided into the normal group, the model group, the low dose Yanshiqiangxin decoction group, the medium dose Yanshiqiangxin decoction group,the high dose Yanshiqiangxin decoction group and the Perindopril group according to the random number table method, with 10 cases in each group. …”
    Get full text
    Article
  5. 41065
  6. 41066
  7. 41067

    Photothermal-enhanced silver nanocluster bioactive glass hydrogels for synergistic antimicrobial and promote wound healing by Fuqiang Song, Anqi Ye, Linyuan Jiang, Yang Lu, Yanzhen Feng, Rong Huang, Siting Du, Xiaoyu Dong, Ting Huang, Ping Li, Liangliang Yang, Jinjing Zhang, Mengjia Xu, Li Cheng, Jian Xiao

    Published 2025-02-01
    “…Here, we introduce a hydrogel incorporating polydopamine-coated bioactive glass (BGs@PDA) on reduced graphene oxide (rGO) with photothermal therapy (PTT) and silver nanoclusters (AgNCs) for synergistic antibacterial treatment. This design enables rapid bacterial eradication and controlled release. …”
    Get full text
    Article
  8. 41068
  9. 41069
  10. 41070
  11. 41071
  12. 41072

    Surgical interventions for spontaneous supratentorial intracerebral haemorrhage: a systematic review and network meta-analysisResearch in context by Jiayidaer Huan, Minghong Yao, Yu Ma, Fan Mei, Yanmei Liu, Lu Ma, Xiaochao Luo, Jiali Liu, Jianguo Xu, Chao You, Hunong Xiang, Kang Zou, Xiao Liang, Xin Hu, Ling Li, Xin Sun

    Published 2025-01-01
    “…However, the superiority of surgery over conservative medical treatment (CMT) and the comparative benefits of different surgical procedures remain unclear. …”
    Get full text
    Article
  13. 41073

    High level non-carbapenemase carbapenem resistance by overlaying mutations of mexR, oprD, and ftsI in Pseudomonas aeruginosa by Yan Yang, Xue Li, Lang Sun, Xiu-Kun Wang, You-Wen Zhang, Jing Pang, Guo-Qing Li, Xin-Xin Hu, Tong-Ying Nie, Xin-Yi Yang, Jian-Hua Liu, Gerrit Brandis, Xue-Fu You, Cong-Ran Li

    Published 2025-01-01
    “…These findings highlight the interplay of different mutations in causing non-carbapenemase carbapenem-resistance in P. aeruginosa.IMPORTANCEThe emergence of carbapenem-resistant Pseudomonas aeruginosa (CRPA) poses a significant global health threat, complicating treatment options for infections caused by this pathogen. …”
    Get full text
    Article
  14. 41074

    Association between PM2.5 components and poor ovarian response in assisted reproductive technology patients: A retrospective cohort study identifying sensitive exposure windows in... by Rui-Ling Liu, Zhi-Lei Xu, Yu-Ling Hu, Xing-Yu Lv, Quan-Zi Yao, Jia-Liang He, Li-Juan Fu, Li-Hong Geng, Tong Wang, Zhao-Hui Zhong, Yi-Jian Zhu, Yu-Bin Ding

    Published 2025-02-01
    “…In this retrospective cohort study, we included 38,619 patients undergoing their first in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) treatment, defining POR as the primary outcome based on the POSEIDON criteria. …”
    Get full text
    Article
  15. 41075

    Hypertension Subtypes among Thai Hypertensives: An Analysis of Telehealth-Assisted Instrument in Home Blood Pressure Monitoring Nationwide Pilot Project by Sakolwat Montrivade, Pairoj Chattranukulchai, Sarawut Siwamogsatham, Yongkasem Vorasettakarnkij, Witthawat Naeowong, Patchaya Boonchayaanant, Anut Sakulsupsiri, Aekarach Ariyachaipanich, Vorarit Lertsuwunseri, Voravut Rungpradubvong, Sudarat Satitthummanid, Sarinya Puwanant, Somchai Prechawat, Suphot Srimahachota, Jarkarpun Chaipromprasit, Wacin Buddhari, Smonporn Boonyaratavej, Surapun Sitthisook, Peera Buranakitjaroen, Apichard Sukonthasarn, Somkiat Sangwatanaroj

    Published 2020-01-01
    “…HT subtypes were classified according to the treatment status, CBP (≥or <140/90 mmHg), and mean HBP (≥or <135/85 mmHg) into the following eight subtypes: in nonmedicated hypertensives, there are four subtypes that are normotension, white-coat HT, masked HT, and sustained HT; in treated hypertensives, there are four subtypes that are well-controlled HT, HT with white-coat effect, masked uncontrolled HT, and sustained HT. …”
    Get full text
    Article
  16. 41076

    Dynamic changes and future trend predictions of the global burden of anxiety disorders: analysis of 204 countries and regions from 1990 to 2021 and the impact of the COVID-19 pande... by Si Chen, Wei Huang, Min Zhang, Yan Song, Chunshan Zhao, Hongwei Sun, Yanyu Wang, Jihong Wang, Yali Sun, Lei Zhou, Yan Zhu, HongYuan Wang, ZhengYang Xu, YuRui Bai, Cheng Chang

    Published 2025-01-01
    “…There is an urgent need for the adoption of targeted prevention and treatment strategies on a global scale, especially in high SDI regions, to effectively address the escalating issue of anxiety disorder burden. …”
    Get full text
    Article
  17. 41077

    Combined Use of Chitosan and Olfactory Mucosa Mesenchymal Stem/Stromal Cells to Promote Peripheral Nerve Regeneration In Vivo by Rui D. Alvites, Mariana V. Branquinho, Ana C. Sousa, Irina Amorim, Rui Magalhães, Filipa João, Diogo Almeida, Sandra Amado, Justina Prada, Isabel Pires, Federica Zen, Stefania Raimondo, Ana L. Luís, Stefano Geuna, Artur S. P. Varejão, Ana C. Maurício

    Published 2021-01-01
    “…The therapeutic combinations studied show promising outcomes and should be the target of new future works to overcome some irregularities found in the results and establish the combination of nerve guidance conduits and olfactory mucosa mesenchymal stem/stromal cells as viable options in the treatment of peripheral nerves after injury.…”
    Get full text
    Article
  18. 41078
  19. 41079

    Mechanical Activation of cPLA2 Impedes Fatty Acid β‐Oxidation in Vein Grafts by Linwei Fan, Yuanjun Tang, Jian Liu, Yueqi Liu, Yiwei Xu, Jiayu Liu, Han Liu, Wei Pang, Yuxuan Guo, Weijuan Yao, Tao Zhang, Qin Peng, Jing Zhou

    Published 2025-01-01
    “…Inadequate fatty acid oxidation caused by knockdown of CPT1B or YY1, or etomoxir treatment, increased nuclear membrane tension, orchestrating the activation of cPLA2. …”
    Get full text
    Article
  20. 41080